Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia.

@article{Sato2008PopulationPO,
  title={Population pharmacokinetics of tebipenem pivoxil (ME1211), a novel oral carbapenem antibiotic, in pediatric patients with otolaryngological infection or pneumonia.},
  author={Nobuo Sato and Koji Kijima and Tomokazu Koresawa and Nayu Mitomi and Jun Morita and Hisashi Suzuki and Hiroyuki Hayashi and Shigeki Shibasaki and Tohru Kurosawa and Kyoichi Totsuka},
  journal={Drug metabolism and pharmacokinetics},
  year={2008},
  volume={23 6},
  pages={434-46}
}
Tebipenem pivoxil (TBPM-PI, ME1211) has been under development as the world's first oral carbapenem for treatment of otolaryngological/respiratory infections caused by drug-resistant S. pneumoniae in pediatric patients. In order to treat these infections effectively, it is important to design optimal dosing regimens based on the pharmacokinetics/pharmacodynamics (PK/PD) relationships, which can be characterized by clarifying the pharmacokinetics of tebipenem (TBPM) in the pediatric population… CONTINUE READING

11 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Tebipenem pivoxil ( TBPM - PI , ME1211 ) has been under development as the world 's first oral carbapenem for treatment of otolaryngological / respiratory infections caused by drug - resistant S. pneumoniae in pediatric patients .
Population pharmacokinetics of tebipenem pivoxil ( ME1211 ) , a novel oral carbapenem antibiotic , in pediatric patients with otolaryngological infection or pneumonia .
All Topics